miR-340与Nrf2在非小细胞肺癌患者靶向治疗耐药中的表达及相关性分析  

Expressions of miR-340 and Nrf2 in NSCLC Patients with Drug Resistance and the Correlation Analysis

作　　者：王伟[1] 金朝晖[1] 范伏元[1] 赵四林[1] 李妲[1] 符艳 孙爽 肖雪飞 张慧卿 闵锐 WANG Wei;JIN Zhaohui;FAN Fuyuan;ZHAO Silin;LI Da;FU Yan;SUN Shuang;XIAO Xuefei;ZHANG Huiqing;MIN Rui(Department of Respiratory Medicine,the First Hospital of Hunan University of Chinese Medicine,Changsha,Hunan,410007,China)

机构地区：[1]湖南中医药大学第一附属医院呼吸科,湖南长沙410007

出　　处：《肿瘤药学》2021年第1期87-90,共4页Anti-Tumor Pharmacy

基　　金：湖南省中医药科技计划项目(201838)。

摘　　要：目的探究miR-340与Nrf2在非小细胞肺癌患者靶向治疗耐药中的表达及意义。方法选取2016年1月—2019年12月我院收治的EGFR基因突变非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)耐药患者42例作为观察组,同期于我院治疗的非耐药患者42例为对照组,检测并比较两组患者miR-340、Nrf2表达水平,同时探究miR-340水平与Nrf2的相关性。结果观察组患者血清miR-340水平显著高于对照组(P<0.05),Nrf2水平显著低于对照组(P<0.05);miR-340与Nrf2水平呈负相关(P<0.05);进一步Logistic分析显示,miR-340表达上调及Nrf2表达下调是非小细胞肺癌患者EGFR-TKIs耐药发生的独立危险因素。结论miR-340可通过影响体内Nrf2水平参与EGFR-TKIs耐药的发生,为提高肺腺癌的诊治提供了新的理论依据及潜在干预靶点。Objective To investigate the expression and significance of miR-340 and Nrf2 in non-small cell lung cancer(NSCLC)patients with resistance to targeted drugs.Methods Totally 42 NSCLC patients who got epidermal growth factor receptor(EGFR)gene mutation and underwent resistance to EGFR tyrosine kinase inhibitors(EGFR-TKIs)between January 2016 and December 2018 were selected as the observation group,and 42 non-resistant patients treated in our hospital during the same period were selected as the control group.Detect and compare the miR-340 and Nrf2 expression levels of the two groups,and explore the correlation between the miR-340 and Nrf2 expression levels.Results The peripheral serum miR-340 expression level was significantly higher in the observation group than in the control group,while the Nrf2 level was lower than in the control group(P<0.05).In addition,the miR-340 expression level was negatively correlated with the Nrf2 expression level(P<0.05).Further logistic analysis showed that up-regulation of miR-340 level and down-regulation of Nrf2 level were independent risk factors for EGFR-TKIs resistance in NSCLC patients.Conclusion miR-340 can participate in the development of EGFR-TKIs resistance by affecting the level of Nrf2 in the patients.It provides a new theoretical basis and potential intervention targets for improving the diagnosis and treatment of lung adenocarcinoma.

关 键 词：非小细胞肺癌 EGFR-TKIS 耐药 miR-340 NRF2 

分 类 号：R734.2[医药卫生—肿瘤]